Purpose/objectives: To determine whether cancer survivors engage in health-promotion behaviors, to evaluate the extent of their experience of psychological distress, and to investigate the relationship between the practice of health-promotion behaviors and psychological distress.
Design: Cross-sectional secondary data analysis.
Setting: A national, face-to-face interview conducted by personnel of the U.S. Census Bureau using a random sampling of American adults.
Sample: 1,784 survey respondents who reported a previous cancer diagnosis.
Methods: Data from the 2009 National Health Interview Survey were used to examine the prevalence of smoking, physical inactivity, alcohol use, and reports of psychosocial distress. Interviews pertained to the amount and distribution of illness, its effects in terms of disability and chronic impairments, and the kinds of health services people receive.
Main Research Variables: Age, current smoking prevalence, alcohol consumption, physical activity, and the experience of feeling hopelessness, sadness, and anxiety.
Findings: Cancer survivors continue to smoke at a rate similar to the national average. Overall, most respondents reported no symptoms of psychological distress. However, age appears to play a major role, showing significant differences in the prevalence of current smoking, participation in physical activity, alcohol use, and reported level of distress.
Conclusions: This study provides estimates of the prevalence of health-promotion behaviors and experience of psychological distress among American cancer survivors. The results reveal opportunities for interventions among cancer survivors.
Implications For Nursing: Nurses should be proactive in providing guidance to survivors regarding the adoption of healthy lifestyle behaviors. Those who encounter younger cancer survivors need to be alert to the higher potential for distress in that population, perform appropriate screenings, and be prepared to offer guidance, supportive care, and referrals for psychological care if needed.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1188/12.ONF.E132-E140 | DOI Listing |
Trials
January 2025
London Centre for Primary Care, Wolfson Institute of Population Health, Queen Mary University of London, London, UK.
Background: The aim of the SURECAN trial is to evaluate a person-centred intervention, based on Acceptance and Commitment Therapy (ACT Plus ( +)), for people who have completed treatment for cancer with curative intent, but are experiencing poor quality of life. We present the statistical analysis plan for assessing the effectiveness and cost-effectiveness of the intervention in improving quality of life 1 year post randomisation.
Methods And Design: SURECAN is a multi-centre, pragmatic, two-arm, partially clustered randomised controlled superiority trial comparing the effectiveness of ACT + added to usual care with usual aftercare.
Ann Surg Oncol
January 2025
Department of Surgery, School of Medicine and Public Health, Wisconsin Surgical Outcomes Research Program, University of Wisconsin, Madison, WI, USA.
Introduction: Little is known about the symptom burden of breast cancer survivors with early-stage disease. Many studies have focused on symptoms of patients who are undergoing or recently completed systemic therapy. However, with the increased use of Oncotype DX, the proportion of early-stage hormone receptor-positive patients who undergo chemotherapy has declined, making existing studies of the symptom experience less useful for these patients.
View Article and Find Full Text PDFPatient Educ Couns
January 2025
College of Nursing, Seoul National University, Seoul, South Korea; Center for World-leading Human-care Nurse Leaders for the Future by Brain Korea 21 (BK 21) four project, College of Nursing, Seoul National University, Seoul, South Korea.
Objectives: This systematic review aimed to identify effective components and assess the statistical, practical, and clinical significance of tailored interventions for enhancing cancer survivors' quality of life.
Methods: Twenty-four clinical trials were selected based on search results from five databases. Study quality was assessed using the Cochrane Risk of Bias Tool 2.
Eur J Obstet Gynecol Reprod Biol
January 2025
Département de chirurgie, centre Léon Bérard, Lyon, France; INSERM U1290 RESHAPE, France; Hôpital Femme Mère Enfant, Bron, France. Electronic address:
Unlike high-grade serous carcinoma (HGSC), which mainly affects postmenopausal women, mucinous ovarian carcinoma (MOC) affects younger patients, with a median age at diagnosis of 53 years, and is rare among premenopausal women. After they receive anticancer treatment, these women encounter specific issues involving fertility preservation (FP) and/or pregnancy, which potentially require assisted reproductive technology (ART) as well as the prescription of hormonal contraception (HC) or hormone replacement therapy (HRT). We reviewed the available literature in PubMed/Medline concerning the risks of the development of ovarian cancer (OC), including MOC, associated with ART, HC and HRT, and literature on the impact of ovarian stimulation in the context of FP and/or ART, HC and HRT in women previously treated for OC, including MOC.
View Article and Find Full Text PDFJ Cancer Surviv
January 2025
School of Nursing, College of Nursing, Taipei Medical University, Taipei, Taiwan.
Purpose: This meta-analysis aims to estimate the global prevalence of severe, moderate, overall malnutrition and moderating factors of malnutrition in colorectal cancer (CRC) survivors.
Methods: A comprehensive search was conducted in Embase, CINAHL, Medline-OVID, PubMed, Scopus, and Web of Science from inception to February 8, 2024, without language, region, or publication date restrictions. A generalized linear mixed model and random-effects model were used to examine the pooled prevalence, and moderator analyses were implemented to investigate variations in the pooled prevalence.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!